Europe Experiences Growth in Digital Therapeutics for Chronic Pain
Berlin, Friday, 7 February 2025.
Digital therapeutics in Europe, especially for chronic pain in rheumatic conditions, are rising. Innovative apps improve patient outcomes, reducing dependency on traditional medications. Germany leads this growth.
Market Growth and Value Projection
The European digital therapeutics market is experiencing remarkable expansion, valued at €1.94 billion in 2024 and projected to reach €3.93 billion by 2030, with a compound annual growth rate of 12.43% [1]. This substantial growth is primarily driven by increasing demand for personalized healthcare solutions, technological advancements, and the rising prevalence of chronic diseases [1]. Germany has emerged as the frontrunner in this digital health revolution [1], supported by its pioneering Digital Healthcare Act (DVG) enacted in 2019, which enables direct prescription of digital health applications [1].
Integration with Healthcare Systems
The transformation of healthcare delivery is particularly evident in Germany’s systematic approach, where doctors can now prescribe digital health applications approved by the Federal Institute for Drugs and Medical Devices (BfArM) [1]. This integration is further strengthened by Germany’s advanced healthcare infrastructure, comprehensive electronic health records (EHRs), and widespread adoption of telemedicine [1]. The collaboration between pharmaceutical companies and digital health startups has created a fertile ground for innovation in evidence-based digital treatments [1].
Impact on Chronic Pain Management
Recent developments in digital therapeutics have shown particular promise in managing chronic pain conditions [2]. As of February 2025, there has been a notable increase in the adoption of digital health solutions across Europe, specifically targeting chronic pain management [2]. This trend is particularly significant given the complex nature of chronic pain conditions and the need for comprehensive treatment approaches that extend beyond traditional pharmacological interventions [GPT].
Future Outlook and Regulatory Support
The regulatory landscape continues to evolve favorably for digital therapeutics. The European Pain Federation has recently strengthened its position on digital health through comprehensive position papers released in early 2025 [3], indicating growing institutional support for digital therapeutic solutions. With the FDA’s recent acceptance of new biological treatments for inflammatory conditions [4], the integration of digital therapeutics with conventional treatments represents a promising direction for comprehensive pain management strategies [GPT].
Bronnen
- www.globenewswire.com
- thejournalofheadacheandpain.biomedcentral.com
- europeanpainfederation.eu
- www.hcplive.com